Company Profile
Assembly Biosciences Stock Price, News & Analysis
- Ticker:
- ASMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.91 USD (+1.41%)
Close
Last updated: July 27, 2026
485M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ASMB closed up 1.41% at $25.91. No new same-company headline was identified in the current news window.
Company overview
Business overview
Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery. Its story is built around trying to translate targeted biology into therapies for difficult infectious diseases.
Geographic Base and Sector Classification
Assembly Biosciences is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology with an antiviral focus.
Business Model Characteristics
The company depends on translational validation, clinical data, and the ability to keep a narrow pipeline funded. Investors watch proof-of-concept work and strategic changes.
Position Within the Biotechnology Landscape
Assembly occupies a niche antiviral and discovery position within biotech. The stock is sensitive to whether its programs can create a real clinical edge.
Future catalysts
Assembly’s catalysts are its hepatitis B and antiviral platform, plus any update that shows the company can still create value from its RNA / small-molecule strategy. The company still needs a cleaner clinical path.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
SPRO · Source: Spero Therapeutics
- 02
- 03
- 04
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
SPRO · Source: Spero Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Assembly Biosciences (ASMB)?
Assembly Biosciences (ASMB) most recently closed at 25.91 USD, a +1.41% move versus the previous session.
What is the market cap of Assembly Biosciences (ASMB)?
Assembly Biosciences currently has a market capitalization of 485M USD on BioPharmSignal.
What does Assembly Biosciences do?
Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery. Its story is built around trying to translate targeted biology into therapies for difficult infectious diseases.
On which exchange is ASMB stock listed?
Assembly Biosciences (ASMB) is associated with NASDAQ, United States, Biopharma.
What is Assembly?
Assembly’s catalysts are its hepatitis B and antiviral platform, plus any update that shows the company can still create value from its RNA / small-molecule strategy.
Which conditions is Assembly Biosciences targeting with Assembly?
Assembly’s catalysts are its hepatitis B and antiviral platform, plus any update that shows the company can still create value from its RNA / small-molecule strategy.
How does Assembly Biosciences describe recent progress with Assembly?
Assembly’s catalysts are its hepatitis B and antiviral platform, plus any update that shows the company can still create value from its RNA / small-molecule strategy.
What is Biosciences?
Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery.